Form 4: Tarsus Pharmaceuticals Director Andrew Goldberg Reports Stock Transactions

Director Andrew Goldberg reports the acquisition of 3,350 shares of Tarsus Pharmaceuticals common stock through the settlement of vested Restricted Stock Units (RSUs).

Summary

• On June 24, 2024, Andrew D. Goldberg, a director of Tarsus Pharmaceuticals, Inc., reported transactions involving the company's common stock.
• Goldberg acquired 3,350 shares of common stock through the settlement of vested Restricted Stock Units (RSUs).
• Following the transaction, Goldberg beneficially owns 6,350 shares of Tarsus Pharmaceuticals common stock.
• The RSUs were granted on June 22, 2023, and vested on the one-year anniversary, contingent upon continuous service as a non-employee director.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates